Ranbaxy Laboratories Closes Plant in the US

Ranbaxy Laboratories has closed a unit in the US as part of a rationalisation process. The plant was under scrutiny by US authorities for violation of regulatory norms. Managing director Arun Sawhney on Friday said the liquid-manufacturing plant in Gloversville, NY, had been shut as it was operating at 'sub-optimal level'. The plant closure is not expected to impact the company's revenues. A company spokesman said only one item of several manufactured at the plant had been manufactured for commercialisation since March, 2010. In December 2009, the US Food and Drug Administration (FDA) had issued a warning to the plant for violation of manufacturing norms and halted approval of new drugs.